✦ LIBER ✦

Imatinib Is Effective in Children With Previously Untreated Chronic Myelogenous Leukemia in Early Chronic Phase: Results of the French National Phase IV Trial

✍ Scribed by Millot, F.; Baruchel, A.; Guilhot, J.; Petit, A.; Leblanc, T.; Bertrand, Y.; Mazingue, F.; Lutz, P.; Verite, C.; Berthou, C.

Book ID: 111898544
Publisher: American Society of Clinical Oncology
Year: 2011
Tongue: English
Weight: 223 KB
Volume: 29
Category: Article
ISSN: 0732-183X
DOI: 10.1200/jco.2010.32.7114

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Imatinib mesylate is effective in childr

Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation

✍ Millot, F; Guilhot, J; Nelken, B; Leblanc, T; De Bont, E S; Békassy, A N; Gadner 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 108 KB

Imatinib in combination with cytarabine

Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: Rationale and design of phase I/II trials

✍ François Guilhot; Martine Gardembas; Philippe Rousselot; Michel Tulliez; Magda V 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 82 KB

Multicenter prospective trial evaluating

Multicenter prospective trial evaluating the tolerability of imatinib for Japanese patients with chronic myelogenous leukemia in the chronic phase: Does body weight matter?

✍ Yoshinobu Kanda; Shinichiro Okamoto; Tetsuzo Tauchi; Masahiro Kizaki; Koiti Inok 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB 👁 2 views

## Abstract Imatinib at a daily dose of 400 mg is the standard treatment for chronic myelogenous leukemia in the chronic phase. However, the feasibility of this dose for small Japanese adults has not been clarified. We prospectively investigated the toxicity and efficacy of this dose in adult Japan

Long-term safety and efficacy of imatini

Long-term safety and efficacy of imatinib mesylate (Gleevec®) in elderly patients with chronic phase chronic myelogenous leukemia: Results of the AFR04 study

✍ Philippe Rousselot; Pascale Cony-Makhoul; Franck Nicolini; François Xavier Mahon 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 177 KB

Bendamustine in Combination With Rituxim

Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group

✍ Fischer, K.; Cramer, P.; Busch, R.; Bottcher, S.; Bahlo, J.; Schubert, J.; Pflug 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 156 KB

Results of triple therapy with interfero

Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in early chronic phase

✍ Susan O'Brien; Francis Giles; Moshe Talpaz; Jorge Cortes; Mary Beth Rios; Jianqi 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 1 views

## Abstract ## BACKGROUND Before the discovery of imatinib mesylate, a Bcr‐Abl selective tyrosine kinase inhibitor, three agents, interferon‐alpha (IFN‐α), cytarabine (ara‐C), and homoharringtonine (HHT), had demonstrated activity against Philadelphia chromosome (Ph)‐positive chronic myelogenous l